- The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
- Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
- The company is positioned to engage several markets, including digital therapeutics and research
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (https://ibn.fm/xOXo9).
Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes. We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of the pharmaceutical-grade product.”
Ibogaine is a psychoactive substance that can be found naturally in the roots of the African iboga tree. The company is actively researching ibogaine as a potential treatment for traumatic brain injury and other related conditions. All preliminary data show that the drug may also yield promising results as a treatment for neuropathic pain and migraines. In addition, research also indicates that ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addiction.
MINDCURE has filed U.S. provisional patent applications for two routes of chemical synthesis of ibogaine. Both routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds. Both are currently under assessment to determine the preferred method for further developing the compound (https://ibn.fm/ojpg5).
Chief Medical Officer Joel Raskin discussed the natural iboga plant as a precious resource, stating, “Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy. Our company’s research team would also have access to this sustainable drug supply.”
MINDCURE is positioned to disrupt several different market spaces through its technology, research, and products, including the digital therapeutics space, which covers health interventions delivered through a smart device to induce a behavioral change in the patient. The company’s leading foray into the digital therapeutics space is iSTRYM, an AI-driven software platform that enables personalized and calculated outcomes in psychedelic therapy.
The global digital therapeutics market was valued at $2.88 billion in 2019, but it is expected to reach $13.8 billion by 2027 with a CAGR of 20.5% during the forecast period (https://ibn.fm/793EJ). The global market for drug addiction therapy, where ibogaine can be a potential game changer, was valued at $17.65 billion in 2019 and is expected to grow at a CAGR of 7% during the forecast period, resulting in a value of $31.17 billion by 2027 (https://ibn.fm/oAI5T).
For more information, visit the company’s website at www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.